Should breathing treatments be continued for hospice patients, and which therapies (e.g., short‑acting bronchodilators versus inhaled corticosteroids) are appropriate to maintain for symptom relief?

Should Breathing Treatments Be Continued for Hospice Patients?

Continue bronchodilators for hospice patients only if they provide documented symptom relief for dyspnea, particularly in those with reversible airway obstruction, but discontinue inhaled corticosteroids and other preventive therapies that do not offer immediate comfort. 1

Treatment Framework Based on Life Expectancy

The NCCN palliative care guidelines provide clear direction stratified by prognosis 1:

For Patients with Months to Weeks of Life Expectancy

• Bronchodilators remain appropriate when treating underlying reversible airflow obstruction that contributes to dyspnea 1
• Continue only if providing subjective relief of breathlessness
• The British Thoracic Society explicitly lists nebulizers for "symptom relief in palliative care" as a valid indication 2

For Patients with Weeks to Days (Actively Dying)

• Focus shifts entirely to comfort measures 1
• Discontinue preventive therapies including inhaled corticosteroids
• Prioritize opioids (morphine 2.5-10 mg PO q 2 hr prn or 1-3 mg IV q 2 hr prn if opioid naive) as first-line for dyspnea 1
• Add benzodiazepines (lorazepam 0.5-1 mg PO q 4 hr prn) if dyspnea is associated with anxiety 1

Specific Breathing Treatment Recommendations

Short-Acting Bronchodilators (SABAs/SAMAs)

Continue these if:

• Patient has known COPD or asthma with reversible obstruction 1
• Patient reports subjective improvement in breathlessness after use 3
• Delivery via nebulizer is appropriate when patients are too ill to use hand-held inhalers 2

Important caveat: Bronchodilators combined with opioids achieve 52% reduction in dyspnea, demonstrating superior efficacy compared to either alone 3. This supports continuing bronchodilators as adjuvant therapy to limit opioid doses and side effects.

Inhaled Corticosteroids (ICS)

Discontinue in most hospice patients because:

• ICS are preventive medications aimed at reducing future exacerbations, not immediate symptom relief 4, 5
• They take weeks to achieve therapeutic effect 6
• Risk of pneumonia and other infections outweighs benefits in end-of-life care 7
• Recent evidence shows high-dose dexamethasone (systemic corticosteroid) provides no benefit for dyspnea in cancer patients with significantly more adverse events 8

Rare exceptions where ICS might continue:

• Stridor from airway inflammation
• Lymphangitic carcinomatosis
• Radiation pneumonitis However, even for these indications, evidence is weak (Grade C) 2

Oxygen Therapy Considerations

Restrict oxygen to patients with SpO2 consistently <90% OR those reporting significant subjective relief 9. Key evidence:

• Most studies show no difference between oxygen and air for breathlessness relief in non-hypoxaemic palliative patients 9
• In the last days of life, oxygen saturation monitoring is irrelevant if the patient appears comfortable 9
• Try a hand-held fan before oxygen—it may be equally effective 9

Practical Implementation Algorithm

Step 1: Assess life expectancy

• Months: Continue bronchodilators if reversible obstruction present; discontinue ICS
• Weeks to days: Transition to comfort-focused care

Step 2: For dyspnea management, prioritize in this order:

1. Opioids (morphine) as first-line 1, 10
2. Bronchodilators as adjuvant if reversible obstruction 1, 3
3. Benzodiazepines if anxiety component 1
4. Non-pharmacologic measures (fans, positioning) 1, 9
5. Oxygen only if SpO2 <90% or patient reports benefit 9

Step 3: Reassess within 3 days

• Discontinue any therapy not providing documented symptom relief 2
• Avoid prolonging treatments that increase burden (mask discomfort, frequent nebulizer sessions) without clear benefit 9

Common Pitfalls to Avoid

1. Continuing preventive medications inappropriately: ICS, long-acting bronchodilators for prevention (not symptom relief), and combination inhalers prescribed for exacerbation prevention have no role in actively dying patients 1

2. Over-relying on oxygen: Oxygen does not relieve dyspnea in non-hypoxaemic patients and may create unnecessary medicalization of dying 9

3. Inadequate opioid dosing: Opioids remain the most evidence-based intervention for dyspnea in palliative care 1, 10. Dose should not be reduced solely for decreased blood pressure or respiratory rate when necessary for symptom control 1

4. Poor inhaler technique: If continuing inhalers, ensure proper technique or switch to nebulizers, as hospice nurses demonstrate only 34.9-67.6% correct technique 11